The Bronx Blood Research Fund provides excellence in research and advances therapy and management of the thalassemias and the hemoglobinopathies.
Current clinical trials by Einstein-Montefiore Division of Hematology faculty, including innovative treatments for sickle cell disease and the epidemiology of Priapism. see listing
The Einstein-Montefiore Division of Hematology has a history of excellence in scientific investigation, including funded research in diverse areas of study:
- embryonic stem cell investigations
- high-throughput red blood cell engineering
- chemically modified hemoglobins and albumin
- in vitro red blood cell production
- murine models of sickle cell disease
- the role of nitric oxide and inflammation on microcirculation
- plasma expanders
- hemoglobin disorders
- thrombosis and hemostasis
Much of this comprehensive activity comes from the combination of resources from the Montefiore (west) and Albert Einstein (east) campuses. Each site has benefited from this integration with enrichment of faculty and postdoctoral and clinical fellows.
Seetharama A. Acharya, Ph.D.
Henny Billett, M.D., M.Sc., FACP
Risk factors for thrombosis and microvascular disease, effect of race and ethnicity on thrombosis, thrombotic and microvascular complications of sickle cell disease.
Eric Bouhassira, Ph.D.
Hematopoietic (blood-forming) stem cells that can differentiate into red cells, T cells, platelets, and all other cell types that comprise blood.
Mary Fabry, Ph.D.
Enzyme mechanisms, water movement across red cell membranes, and oxygenation and perfusion in transgenic mouse models of hemoglobinopathies.
Paul S. Frenette, MD
How hematopoietic stem cells (HSCs) and mature blood cells traffic in vivo.
Ellen W. Friedman, MD
John M. Greally, MB, BCh, PhD
Epigenetic regulation of gene expression.
Rhoda Hirsch, Ph.D.
Hemoglobinopathy HbE (β26 Glu →Lys) and its related diseases
Dhananjay Kaul, Ph.D.
Mechanisms of vascular dysfunction in hemolytic disorders such as sickle cell disease and thalassemia.
Jacob Rand, M.D.
Effects of antiphospholipid (aPL) antibodies on an anticoagulant protein, annexin A5 (previously known as annexin V).
Michael B. Stemerman, M.D.
LDL alters the function of the vascular endothelium and this alteration may be an important mechanism for the development of atherosclerosis.